title: Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
abstract: Steroid refractory acute graft-versus-host-disease of the gut is a serious complication associated with high mortality after allogeneic stem cell transplantation. Treatment options are limited and not predictably effective. We describe the treatment of steroid-refractory acute graft-versus-host-disease with vedolizumab, an antibody directed against integrin α4β7, in 6 patients. All patients responded, and 4 of 6 patients are alive with a median follow-up of 10 months.
authors: Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Electronic address: yfl70@me.com.
authors: Yngvar
authors: Y
authors: Fløisand
authors: Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Department of Gastroenterology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Centre for Immune Regulation, University of Oslo, Oslo, Norway.
authors: Knut E A
authors: KEA
authors: Lundin
authors: Department of Hematology and Oncology, Skåne University Hospital, Lund, Sweden.
authors: Vladimir
authors: V
authors: Lazarevic
authors: Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors: Jørn Dehli
authors: JD
authors: Kristiansen
authors: Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors: Liv T N
authors: LTN
authors: Osnes
authors: Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
authors: Geir E
authors: GE
authors: Tjønnfjord
authors: Department of Pathology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors: Henrik Mikael
authors: HM
authors: Reims
authors: Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors: Tobias
authors: T
authors: Gedde-Dahl
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D016023:Integrins / Q000187:drug effects*; D007410:Intestinal Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016879:Salvage Therapy / Q000379:methods; D013256:Steroids / Q000627:therapeutic use; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D016023:Integrins; D013256:Steroids; C071777:integrin alpha4beta7; C543529:vedolizumab
keywords: Graft-versus-host disease; Gut GVHD; Integrin; Stem cell transplant; Steroid refractory; Vedolizumab